When services can be administered in various settings, the Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member’s medical needs and condition. This decision is based on the member’s current medical condition and any required monitoring or additional services that may coincide with the delivery of this service.
This Medical Policy Bulletin document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy Bulletin will be reviewed regularly and be updated as scientific and medical literature becomes available. For more information on how Medical Policy Bulletins are developed, go to the About This Site section of this Medical Policy Web site.
American Psychiatric Association. Neurodevelopmental Disorders. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Arlington, VA: American Psychiatric Association, 2013: 50-59.
American Speech-Language-Hearing Association (ASHA). Autism overview. [ASHA Web site]. Available at: http://www.asha.org/Practice-Portal/Clinical-Topics/Autism/. Accessed June 03, 2019.
Anagnostou E, Zwaigenbaum L, Szatmari P, et al. Autism spectrum disorder: advances in evidence-based practice. [Clinicalkey Web site]. 04/15/2014. Available at:
https://www.clinicalkey.com/#!/content/journal/1-s2.0-S0820394614601619. Accessed June 03, 2019.
Assembly Committee Substiture for Assembly, No. 2238. State of New Jersey 213th Legislature. [State of New Jersey Web site]. 05/18/2009. Available at:
http://www.njleg.state.nj.us/2008/Bills/A2500/2238_R1.PDF. Accessed June 03, 2019.
Augustyn M, von Hahn LE. Autism spectrum disorder: Evaluation and diagnosis. [UpToDate Web site]. 01/29/2019. Available at:
https://www.uptodate.com/contents/autism-spectrum-disorder-evaluation-and-diagnosis?search=autism%20and%20genetic%20testing&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 [via subscription only]. Accessed June 03, 2019.
Behavior Analyst Certification Board (BACB). About BACB. [BACB Web site]. Available at:
http://www.bacb.com/index.php?page=1. Accessed June 03, 2019.
Behavior Analyst Certification Board (BACB). Become credentialed. [BCAB web site]. 2018. Available at: http://bacb.com/become-credentialed/. Accessed June 03, 2019.
Blue Cross Blue Shield Association (BCBSA) Technology Evaluation Center. Early intensive behavioral intervention and other behavioral interventions for autism spectrum disorder [technology assessment]. Assessment Program Volume 30, No. 1. March 2015. Also available online at: https://pdfs.semanticscholar.org/9b50/0be7d5b914842676f603f6129ca2cacf32e5.pdf. Accessed June 03, 2019.
Brandler WM, Sebat J. From de novo mutations to personalized therapeutic interventions in autism. Annu Rev Med.2015;66(1):487-507.
Bridgemohan C. Screening tools for autism spectrum disorders. [UpToDate Web site]. 01/23/2019. Available at: http://www.uptodate.com/contents/screening-tools-for-autism-spectrum-disorders?view=print. Accessed June 03, 2019.
Behavior Analyst Certification Board, Inc. (BACB). Applied behavior analysis treatment of autism spectrum disorder: practice guidelines for healthcare funders and managers. [BACB Web site]. 2014. Available at:
https://www.bacb.com/wp-content/uploads/2017/09/ABA_Guidelines_for_ASD.pdf. Accessed June 03, 2019.
Blumberg S, Zablostsky B, Avila RM, et al. Diagnosis lost: differences between children who had and who currently have an autism spectrum disorder diagnosis. Autism. 2016; 20(7):783-795.
Boyd BA, Hume K, McBee MT, et al. Comparative efficacy of LEAP, TEACCH and non-model-specific specialeducation programs for preschoolers with autism spectrum disorders. J Autism Dev Disord. 2014;44(2):366-380.
Celestino-Soper PB, Skinner C, Schroer R, et al. Deletions in chromosome 6p22.3-p24.3, including ATXN1, are associated with developmental delay and autism spectrum disorders. [Molecular cytogenetics Web site]. 2012. Available at: http://www.molecularcytogenetics.org/content/pdf/1755-8166-5-17.pdf. Accessed June 03, 2019.
Centers for Disease Control and Prevention. Autism spectrum disorder (ASD). Screening and diagnosis for healthcare providers. [CDC Web site]. 04/26/2018. Available at:
http://www.cdc.gov/ncbddd/autism/hcp-screening.html. Accessed June 03, 2019.
Centers for Disease Control and Prevention. Autism spectrum disorder (ASD). Recommendations and guidelines. [CDC Web site]. 04/26/2018. Available at:
http://www.cdc.gov/ncbddd/autism/hcp-recommendations.html. Accessed June 03, 2019.
Centers for Disease Control and Prevention (CDC). Autism spectrum disorders (ASDs). Data & statistics. Prevalence. [CDC Web site]. 04/05/2019. Available at:
Centers for Disease Control and Prevention (CDC). Community report from the autism and developmental disabilities monitoring (ADDM) network. [CDC Web site]. 2012. Available at:http://www.cdc.gov/ncbddd/autism/documents/ADDM-2012-Community-Report.pdf. Accessed April 24, 2018.
Centers for Disease Control and Prevention (CDC). Fragile X syndrome. [CDC Web site]. 06/01/2017. Available at: http://www.cdc.gov/ncbddd/fxs/index.html. Accessed April 24, 2018. Accessed June 03, 2019.
Cohen H, Amerine-Dickens M, Smith T. Early intensive behavior treatment: replication of the UCLA model in a community setting. Developmental and Behavior Pediatrics.2006;27:S145-S155.
Cooper AS, Friedlaender E, Levy SE, et al. The implications of brain MRI in autism spectrum disorder. J Child Neurol. 2016;31(14):1611-1616.
Cooper GM, Coe BP, Girirajan S, et al. A copy number variation morbidity map of developmental delay. Nature genetics. 2011;43(9):838-846.
Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. Genet Med. 2011;13(9):770-776.
Dawson G, Jones EJ, Merkle K, et al. Early Behavior intervention is associated with normalized brain activity in young recipient with autism. J Am Acad Recipient Adolesc Psychiatry. 2012;51(11):1150-1159.
Eapen V. Genetic basis of autism. Is there a way forward? [Medscape Web site]. 05/25/2011. Available at: http://www.medscape.com/viewarticle/740452. Accessed June 03, 2019.
Eikeseth, S. Outcome of comprehensive psycho-educational interventions for young recipient with autism. Research in Developmental Disabilities. 2009;30(1):158-178.
Eikeseth S, Smith T, Jahr E, et al. Intensive behavior treatment at school for 4- to 7-year-old recipient with autism: A 1-year comparison controlled study. Behavior Modification. 2002;26(1):49-68.
Eldevik S, Hastings RP, Hughes JC, et al. Using participant data to extend the evidence base for intensive behavior intervention for recipient with autism. American Journal on Intellectual and Developmental Disabilities. 2010;115(5):381-405.
Eldevik S, Hastings RP, Hughes JC, et al. Analysis of early intensive Behavior intervention for recipient with autism. Journal of Clinical Recipient and Adolescent Psychology. 2009;38(3):439-450.
Estes A, Munson J, Rogers SJ, et al. Long-term outcomes of early intervention in 6-year-old recipient with autism spectrum disorder. J Amer Acad Recipient Adolesc Psychiatry.2015;54(7):580-587.
Fein D, Barton M, Eigsti IM, et al. Optimal outcome in individuals with a history of autism. J Recipient Psychol Psychiatry. 2013;54(2):195-205.
Foxx, R. M. Applied behavior analysis treatment of autism: the state of the art. Recipient and Adolescent Psychiatric Clinics of North America. 2008;17(4):821-834.
Goods KS, Ishijima E, Chang Y, et al. Preschool based JASPER intervention in minimally verbal recipient with autism: pilot RCT. J Autism Dev Disord. 2013;43(5):1050-1056.
Granpeesheh D, Tarbox J, Dixon DR. Applied behavior analytic interventions for recipient with autism: a description and review of treatment research. Ann Clin Psychiatry. 2009; 21(3):162-73.
Green G, Brennan L, Fein D. Intensive Behavior treatment for a toddler at high risk for autism. Behavior Modification. 2002;26(1):69-102.
Grozeva D, Carss K, Spasic-Boskovic O, et al. Targeted next-generation sequencing analysis of 1,000 individuals with intellectual disability. Hum Mutat. 2015;36(12):1197-1204.
Filipek PA, Accardo PJ, Ashwal S, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology. 2000; 22;55(4):468-479.
Fombone E. Prevalence of childhood disintegrative disorder. Autism. 2002;6(2):149-157.
Freitag CM, Staal W, Klauck SM, et al. Genetics of autistic disorders: review and clinical implications. Eur Child Adolesc Psychiatry. 2010;19(3):169-178.
Friedman JM. High-resolution array genomic hybridization in prenatal diagnosis. Prenat Diagn. 2009;29(1):20-28.
General Assembly of Pennsylvania. House Bill #1150. [State of Pennsylvania Web site]. 07/01/08. Available at:http://www.legis.state.pa.us/CFDOCS/Legis/PN/Public/btCheck.cfm?txtType=PDF&sessYr=2007&sessInd=0&billBody=H&billTyp=B&billNbr=1150&pn=4133. Accessed June 03, 2019.
Grzadzinski R,Huerta M, Lord C. DSM-5 and autism spectrum disorders (ASDs): an opportunity for identifying ASD subtypes. [Molecular Autism Web site]. 05/15/2013. Available at: http://www.molecularautism.com/content/4/1/12. Accessed June 03, 2019.
Hanley GP, Iwata BA, McCord BE. Functional analysis of problem behavior: A review. J Appl Behav Anal. 2003;36(2): 147-185.
Hanley GP, Jin CS, Vanselow NR, et al. Producing meaningful improvement in problem behavior of recipient with autism via synthesized analyses and treatments. J Appl Behav Anal. 2014;47(1):16-36.
Hayes, Inc. Hayes Genetic Test Evaluation (Synopsis). Single Nucleotide Polymorphism (SNP) Chromosomal Microarray Analysis for Intellectual Disability, Developmental Delay, and/or Multiple Congenital Anomalies. Lansdale, PA: Hayes, Inc.; August, 2011.
Heitzman-Powell LS, Buzhardt J, Rusinko LC, Miller, et al. Formative evaluation of an ABA outreach training program for parents of recipient with autism in remote areas. Focus on Autism and Other Developmental Disabilities. 2014;29(1): 23-38.
Herman GE, Henninger N, Ratliff-Schaub K, et al. Genetic testing in autism: how much is enough? [Nature Web site]. 02/09/2007. Available at:
http://www.nature.com/gim/journal/v9/n5/full/gim200746a.html. Accessed June 03, 2019.
Howard JS, Sparkman CR, Cohen HG, et al. A comparison of intensive behavior analytic and eclectic treatments for young recipient with autism. Research in Developmental Disabilities. 2005;26(4):359-383.
Howard JS, Stanislaw H, Green G, et al. Comparison of behavior analytic and eclectic early interventions for young recipient with autism after three years. Res Dev Disabil. 2014;35(12):3326-3344.
Huerta M, Bishop SL, Duncan A, Hus V, et al. Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV piagnoses of Pervasive developmental disorders. Am J Psychiatry. 2012;169(10):1056-1064.
Jobe TH, Gavira M, Kovilparambil A, eds. Clinical Neuropsychiatry.Malden, MA: Blackwell Science, Inc.; 1997.
Johnson CP, Myers SM, American Academy of Pediatrics (AAP) Council on Children with Disabilities. Clinical report: identification and evaluation of children with autism spectrum disorders. Pediatrics.2007;120(5):1183-1215. (Reaffirmed: 08/2014). Also available on the AAP Web site at: https://pediatrics.aappublications.org/content/pediatrics/120/5/1183.full.pdf. Accessed June 03, 2019.
Kalsner L, Twachtman-Bassett J, Tokarski K, et al. Genetic testing including targeted gene panel in a diverse clinical population of children with autism spectrum disorder: Findings and implications. Mol Genet Genomic Med. 2018;6(2):171-185.
Kamio Y, Haraguchi H, Miyake A, et al. Brief report: large individual variation in outcomes of autistic recipient receiving low intensity behavior interventions in community settings. Child Adolesc Psychiatry Ment Health. 2015;9:6.
Kearney HM, South ST, Wolff DJ, et al. American College of Medical Genetics recommendations for the design and performance expectations for clinical genomic copy number microarrays intended for use in the postnatal setting for detection of constitutional abnormalities. Genet Med. 2011;13(7):676-679.
Kearney HM, Thorland EC, Brown KK, et al. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med. 2011;13(7):680-685.
Koegel LK, Koegel RL, Ashbaugh K, et al. The importance of early identification and intervention for recipient with or at risk for autism spectrum disorders. Int J Speech Lang Pathol. 2014;6(1):50-56.
Lowe TL, Tanaka K, Seashore MR, , et al. Detection of phenylketonuria in autistic and psychotic children. JAMA. 1980;243(2):126-128.
Landa RJ, Kalb LG. Long-term outcomes of toddlers with autism spectrum disorders exposed to short-term intervention. Pediatrics.2012;130 Suppl 2:186-190.
LeBlanc LA, Gillis G. Behavior interventions for recipient with autism spectrum disorders. Pediatr Clin North Am. 2012;59(1):147-64.
Lovaas O I. Behavior treatment and normal educational and intellectual functioning in young autistic recipient. Journal of Consulting and Clinical Psychology.1987;55(1), 3-9.
MacDonald R, Parry-Cruwys D, Dupere S, et al. Assessing progress and outcome of early intensive behavior intervention for toddlers with autism. Res Dev Disabil. 2014;35(12):3632-3644.
Maglione MA, Gans D, Das L, et al. Nonmedical interventions for recipient with ASD: recommended guidelines and further research needs. Pediatrics.2012;130(2):169-178.
Malik S. Role of applied behavior analysis in behavior modification of autistic recipient. Int J Med Appl Health. 2013;1(2):52-59.
Manning M, Hudgins L. The American College of Medical Genetics (ACMG) Practice Guidelines. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med. 2010; 12(11): 742–745.
Matson J L, Benavidez D A, Compton L S, et al.
Behavior treatment of autistic persons: A review of research from 1980 to the present. Res Dev Disabil.1996;17(6):433-465.
McEachin J J, Smith T, Lovaas O I. Long-term outcome for recipient with autism who received early intensive behavior treatment. Am Jon Ment Retard.1993;97(4):359-372.
Mefford HC, Batshaw ML, Hoffman EP. Genomics, intellectual disability, and autism. N Engl J Med. 2012;366: 733-743.
Michelson DJ, Shevell MI, Sherr EH, et al. Evidence Report: Genetic and metabolic testing on children with global developmental delay: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2011;77(17):1629-1635.
Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-764.
Moeschler JB, Shevell M. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics.2014;134(3):903-918.
Mohammadzaheri F, Koegel L, Rezaee M, et al. Randomized clinical trial comparison between pivotal response treatment (PRT) and structured applied behavior analysis (ABA) intervention for recipient with autism. J Autism Dev Disord.
Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics.2004;113(5):e472-e486.
Myers SM, Johnson CP, American Academy of Pediatrics (AAP) Council on Children with Disabilities. Management of children with autism spectrum disorders. Pediatrics.2007;120(5):1162-1182. (Reaffirmed: 2014). Also available on the AAP Web site at: http://pediatrics.aappublications.org/cgi/reprint/120/5/1162. Accessed June 03, 2019.
National Autism Center . National Standards Project. Findings and conclusions: national standards project, phase 2. [National Autism Center Website]. 2015. Available at: https://www.nationalautismcenter.org/national-standards-project/phase-2/ . Accessed June 03, 2019.
National Conference of State Legislatures (NCSL). Autism and Insurance Coverage. [NCSL Web site]. 08/08/2018. Available at:http://www.ncsl.org/research/health/autism-and-insurance-coverage-state-laws.aspx. Accessed June 03, 2019.
National Institute of Child Health and Human Development (NICHD). Autism Spectrum Disorder (ASD). [NICHD Web site]. 03/25/2019. Available at: http://www.nichd.nih.gov/health/topics/autism/Pages/default.aspx. Accessed June 03, 2019.
National Institute of Child Health and Human Development (NICHD). Rett syndrome. [NICHD Web site]. 12/01/2016. Available at: https://www.nichd.nih.gov/health/topics/rett. Accessed June 03, 2019.
National Institute of Mental Health (NIMH). Autism spectrum disorder. Overview. [NIMH Web site]. March 2018. Available at: http://www.nimh.nih.gov/health/topics/autism-spectrum-disorders-asd/index.shtml. Accessed June 03, 2019.
National Library of Medicine (NLM). Genetic Home Reference: Phosphatase and tensin homolog (PTEN). [NLM Web site]. 05/28/2019. Available at: http://ghr.nlm.nih.gov/gene/PTEN. Accessed June 03, 2019.
Odom SL, Boyd BA, Hall LJ, et al. Evaluation of comprehensive treatment models for individuals with autism spectrum disorders. Journal of Autism and Developmental Disorders. 2010;40(4)425-436.
Orinstein AJ, Helt M, Troyb E, et al. Intervention for optimal outcome in recipient and adolescents with a history of autism. J Dev Behav Pediatr. 2014;35(4):247-256.
Pennsylvania Department of Education. Bureau of Special Education. Pennsylvania Training and Technical Assistance Network (PaTTAN). Functional behavioral assessment process. [PaTTAN Web site]. 04/01/2019. Available at:
https://www.pattan.net/publications/functional-behavioral-assessment-process/ . Accessed June 03, 2019.
Pennsylvania Department of Human Services. PA Autism Insurance Act (Act 62). Available at: http://www.dhs.pa.gov/provider/paautisminsuranceact62/#.VvPwQeIrLIU. Accessed June 03, 2019.
Redin C, Gerard B, Lauer J, et al. Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. J Med Genet. 2014;51(11):724-736.
Reichow B, Barton EE, Boyd BA, et al. Early intensive behavior intervention (EIBI) for young recipient with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012.
Rogers S, Estes A, Lord C, et al. Effects of a brief early start denver model (ESDM)-based parent intervention on toddlers at risk for autism spectrum disorders: a randomized controlled trial. J Am Acad Recipient Adolesc Psychiatry. 2012;51(10):1052-1065.
Ringwalt, S. The National Early Childhood Technical Assistance Center (NECTAC). Developmental screening and assessment instruments with an emphasis on social and emotional development for young children ages birth through five. [NECTAC Web site]. May 2008. Available at: http://www.nectac.org/~pdfs/pubs/screening.pdf. Accessed June 03, 2019.
Saam J, Gudgeon J, Aston E, et al. How physicians use array comparative genomic hybridization results to guide patient management in children with developmental delay. Genet Med.2008;10(3):181-186.
Sanders SJ, Murtha MT, Gupta AR et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature.2012;485(7397):237-241.
Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. [American College of Medical Genetics and Genomics Web site]. 03/21/2013. Available at:https://www.acmg.net/docs/pp-g-ASD-schaffer-aop-gim201332a.pdf. Accessed June 03, 2019.
Schoumans J, Ruivenkamp C, Holmberg E, et al. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). J Med Genet. 2005;42(9):699-705.
Shaw-Smith C, Redon R, Rickman L, et al. Microarray based comparative genomic hybridization (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disabilities/mental retardation and dysmorphic features. J Med Genet.2004;41(4):241-248.
Shen Y, Dies KA, Holm IA, et al., American Academy of Pediatrics (AAP). Clinical genetic testing for patients with autism spectrum disorders. 2010;125(4):727-735.
Smith DG, Ehlers MD. Mining and remodeling human genetics for autism therapeutics. [Pub Med Web site]. 10/22/2012. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22483267. Accessed June 03, 2019.
State of New Jersey Department of Banking and Insurance (DOBI). Bulletin No: 10-02. [State of New Jersey DOBI Web site]. 01/14/2010. Available at: http://www.state.nj.us/dobi/bulletins/blt10_02.pdf. Accessed June 03, 2019.
Steenhuysen, J. Gene studies begin to unravel autism puzzle. [Medscape Web site]. 04/04/2012. Available at: http://www.medscape.com/viewarticle/761544?src=ptalk. Accessed June 03, 2019.
Sallows GO, Graupner TD. Intensive Behavior treatment for recipient with autism: four-year outcome and predictors. Am J Ment Retard. 2005;110(6):417-438.
Smith T, Groen AD, Wynn JW. Randomized trial of intensive early intervention for recipient with pervasive developmental disorder. Am J Ment Retard.2000;105(4):269-285.
South ST, Lee C, Lamb AN, et al. ACMG standards and guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013. Genet Med. 2013;15(11):901-909.
Tarbox RSF, Najdowski AC. Discrete trial training as a teaching paradigm. In: Luiselli JK, Russo DC, Christian WP, Wilczynski SM, editors. Effective Practices for Recipients with Autism . New York: Oxford University Press; 2008. p. 181-194.
Tsuchiya KD, Shaffer LG, Aradhya S, et al. Variability in interpreting and reporting copy number changes detected by array-based technology in clinical laboratories. Genet Med. 2009;11(12):866-873.
Tuberous sclerosis (TS) Alliance. Tuberous sclerosis and autism spectrum disorders. [TS Alliance Web site]. September 2013. Available at: https://www.tsalliance.org/about-tsc/signs-and-symptoms-of-tsc/brain-and-neurological-function/tsc-and-autism-spectrum-disorders/ . Accessed June 03, 2019.
US Food and Drug Administration (FDA). FDA approves the first drug to treat irritability associated with autism, risperdal. [FDA Web site]. 10/06/2006. Available at:
http://www.drugs.com/newdrugs/fda-approves-risperdal-irritability-associated-autism-1148.html. Accessed June 03, 2019.
US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. ABILIFY (aripiprazole). Prescribing information. [FDA Web site]. 04/04/2002. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s036,021866s021,021729s020,021713s028lbl.pdf. Accessed June 03, 2019.
US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. SecreFlo™ (secretin) for injection. Approval letter. [FDA Web site]. 04/04/2002. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21136ltr.pdf. Accessed June 03, 2019.
Virués-Ortega, J. Applied behavior analytic intervention for autism in early recipient hood: Meta-analysis, meta regression and dose–response meta-analysis of multiple outcomes. Clin Psychol Rev.2010;30(4):387-399.
Volkmar FR, Rhea P, Klin A, Cohen DJ, eds. Handbook of Autism and Pervasive Developmental Disorders. Volumes I and II. 3rd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2005.
Volkmar FR, Rutter M. Childhood disintegrative disorder: results of the DSM-IV autism field trial. J Am Acad Child Adoles Psychiatry. 1995;34(8):1092-1095.
Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry.Feb 2014; 53(2):237-257.
Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice Parameter for the assessment and treatment of recipient and adolescents with autism spectrum disorder. J Am Acad Recipient Adolesc Psychiatry. 2014;53(2):237-257.
Weitlauf AS, McPheeters ML, Sathe N, et al. Therapies for Recipients with Autism Spectrum Disorder: Behavior interventions update. Agency for Healthcare Research and Quality 2014.
Wong C, Odom S L, Hume K, et al. Evidence - based practices for recipient, youth, and young adults with autism spectrum disorder. J Autism Dev Disord. 2015;45(7):1951-1966.
Warren Z, McPheeters ML, Sathe N, et al., American Academy of Pediatrics (AAP). A systematic review of early intensive intervention for autism spectrum disorders. Pediatrics.2011;127(5)1322-1325.
Warren Z, McPheeters ML, Sathe N, et al. A systematic review of early intensive intervention for autism spectrum disorders. Pediatrics. 2011;127(5):1303-1311.
Weissman L, Bridgemohan C. Autism spectrum disorder in children and adolescents: Behavioral and educational interventions. [UpToDate Web site]. 06/28/2018. Available at:
https://www.uptodate.com/contents/autism-spectrum-disorder-in-children-and-adolescents-behavioral-and-educational-interventions?search=applied%20behavioral%20analysis&source=search_result&selectedTitle=1~15&usage_type=default&display_rank=1 [via subscription only]. Accessed June 03, 2019.
Xiang B, Li A, Valentin D et al. Analytical and clinical validity of whole-genome oligonucleotide array comparative genomic hybridization for pediatric patients with mental retardation and developmental delay. Am J Med Genet A. 2008;146A(15):1942-1954.
F84.0 Autistic disorder
F84.2 Rett's syndrome
F84.3 Other childhood disintegrative disorder
F84.5 Asperger's syndrome
F84.8 Other pervasive developmental disorders
F84.9 Pervasive developmental disorder, unspecified
AF Speciality Physician
AH Clinical Psychologist
AJ Clinical Social Worker
HM Less than Bachelor Degree level
HN Bachelors Degree level
HO Masters Degree level
HP Doctoral Level
UN 2 patients serviced
UP 3 patients serviced
UQ 4 patients serviced
UR 5 patients serviced
US 6 or more patients serviced
Policy: 05.00.32i:Speech and Non-Speech Generating Devices
Policy: 05.00.44k:Repair and Replacement of Durable Medical Equipment (DME)
Policy: 07.00.02i:Intravenous Chelation Therapy
Policy: 07.00.03n:Full-Body Monoplace or Multiplace Chamber Hyperbaric Oxygen Therapy
Policy: 07.03.03g:Medical Evaluation and Management for Attention-Deficit Hyperactivity Disorder (ADHD)
Policy: 07.03.08i:Neuropsychological Testing for Neurologically Based Conditions
Policy: 10.03.01j:Physical Medicine, Rehabilitation, and Habilitation Services
Policy: 10.03.01k:Physical Medicine, Rehabilitation, and Habilitation Services
Policy: 10.06.01l:Speech Therapy
Policy: 12.00.03f:Complementary and Integrative Health Services
Policy: 06.02.35w:Genetic Testing (Independence Administrators)